Pimecrolimus cream 1% is effective in asteatotic eczema: Results of a randomized, double-blind, vehicle-controlled study in 40 patients

Journal of the European Academy of Dermatology and Venereology

Volumn 21, Issue 1, 2007, Pages 90-94

  Schulz, P ^a   Bunselmeyer, B ^a   Brautigam M ^b   Luger, T A ^a,c  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b NOVARTIS PHARMA GMBH   (Germany)

^c UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Asteatotic; Corticosteroids; Eczema; Pimecrolimus; Pruritus; Xerosis

Indexed keywords

DRUG VEHICLE; PIMECROLIMUS;

ADULT; AGED; ARTICLE; ASTEATOTIC ECZEMA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CONTROL; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRY SKIN; ECZEMA; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SELF EVALUATION; STATISTICAL ANALYSIS; UNSPECIFIED SIDE EFFECT;

ADULT; DERMATOLOGIC AGENTS; ECZEMA; FEMALE; HUMANS; MALE; MIDDLE AGED; TACROLIMUS; VEHICLES;

EID: 33845645978     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2006.01879.x     Document Type: Article

References (24)

1. Norman RA. Xerosis and pruritus in the elderly: Recognition and management. Dermatologic Ther 2003; 16: 254-259.
2. Elias PM, Choi EH. Interactions among stratum corneum defensive functions. Exp Dermatol 2005; 14: 719-727.
3. Fitzpatrick TB, Johnson R, Wolff K. Asteatotic dermatitis. In: Fitzpatrick TB, ed. Color Atlas and Synopsis of Clinical Dermatology, 3rd edn, McGraw-Hill, New York, 1997: 75.
4. Wellington K, Noble N. Pimecrolimus. A review of its use in atopic dermatitis. Am J Clin Dermatol 2004; 5: 479-495.
5. Queille-Roussel C, Paul C, Duteil L et al. The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for four weeks: A randomised, double-blind controlled study. Br J Dermatol 2001; 144: 507-513.
6. Hanifin JM, Thurston M, Omoto M et al. The eczema area and severity index (EASI): Assessment of reliability in atopic dermatitis. EASI evaluator group. Exp Dermatol 2001; 10: 11-18.
7. Graham-Brown RAC, Grassberger M. Pimecrolimus: A review of preclinical and clinical data. Int J Clin Pract 2003; 57: 319-327.
8. Luger T, Van Leent EJM, Graeber M et al. SDZASM 981: An emerging safe and effective treatment for atopic dermatitis. Br J Dermatol 2001; 144: 788-794.
9. Eichenfield LF, Lucky AW, Boguniewicz M et al. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of atopic dermatitis in children and adolescents. J Am Acad Dermatol 2002; 46: 495-504.
10. Meurer M, Fölster-Holst R, Wozel G et al. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in adults: A six-month study. Dermatology 2002; 205: 271-277.
11. Kapp A, Papp K, Bingham A et al. Efficacy and safety of pimecrolimus cream, a novel non-steroid anti-inflammatory, in long-term management of atopic dermatitis in infants. J Allergy Clin Immunol 2002; 110: 277-284.
12. Wahn U, Bos JD, Goodfield M et al. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. EPediatrics 2002: 110: e2.
13. Kaufmann R, Fölster-Holst R, Höger P et al. Onset of action of pimecrolimus cream 1% in the treatment of atopic eczema in infants. J Allerg Clin Immuol 2004; 114: 1183-1188.
14. Rigopoulos D, Ioannides D, Kalogeromitros D, Gregoriou S, Katsambas A. Pimecrolimus cream 1% vs. betamethasone 17-valerate 0.1% cream in the treatment of seborrhoeic dermatitis. A randomized open-label clinical trial. Br J Dermatol 2004; 151: 1071-1075.
15. Belsito DV, Fowler JF Jr, Marks JG Jr et al. Pimecrolimus cream 1%: A potential new treatment for chronic hand dermatitis. Cutis 2004; 73: 31-38.
16. Gribetz C, Ling M, Lebwohl M et al. Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: A double-blind, randomized study. J Am Acad Dermatol 2004; 51: 731-738.
17. Kreuter A, Hochdorfer B, Altmeyer P, Gambichler T. Pimecrolimus 1% cream for perianal atopic dermatitis. Br J Dermatol 2005; 152: 176-198.
18. Kreuter A, Gambichler T, Breuckmann F et al. Pimecrolimus 1% cream for cutaneous lupus erythematosus. J Am Acad Dermatol 2004; 51: 407-410.
19. Lonsdale-Eccles AA, Velangi S. Topical pimecrolimus in the treatment of genital lichen planus: A prospective case series. Br J Dermatol 2005; 153: 390-394.
20. Goldstein AT, Marinoff SC, Christopher K. Pimecrolimus for the treatment of vulvar lichen sclerosus: A report of 4 cases. J Reprod Med 2004; 49: 778-780.
21. Breuer K, Bräutigam M, Kapp A, Werfel T. Influence of pimecrolimus cream 1% on different morphological signs of eczema in infants with atopic dermatitis. Dermatology 2004; 209: 314-320.
22. Kao JS, Fluhr JW, Man MQ et al. Short-term glucocorticoid treatment compromises both permeability barrier homeostasis and stratum corneum integrity: Inhibition of epidermal lipid synthesis account for functional abnormalities. J Invest Dermatol 2003; 120: 456-464.
23. Sheu HM, Lee JYY, Chai CY, Kuo KW. Depletion of stratum corneum intercellular lipid lamellae and barrier function abnormalities after long-term topical corticosteroids. Br J Dermatol 1997; 136: 884-890.
24. Cork M. Skin barrier damage: Cause or consequence of atopic dermatitis? (Abstract) J Am Acad Dermatol 2005; 52: P9.